STRO

Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.

Wall Street analysts forecast STRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STRO is 2.20 USD with a low forecast of 0.80 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sutro Biopharma Inc revenue for the last quarter amounts to 9.69M USD, increased 13.77 % YoY.

Sutro Biopharma Inc. EPS for the last quarter amounts to -6.70 USD, increased 12.61 % YoY.

Sutro Biopharma Inc (STRO) has 310 emplpoyees as of January 10 2026.

Today STRO has the market capitalization of 100.03M USD.